| TTM
|
12/31/2025
|
12/31/2024
|
12/31/2023
|
12/31/2022
|
|
|---|---|---|---|---|---|
| Total Revenue
|
60,695 | 52,225 | 41,016 | 31,785 | 27,177 |
| Cost of Revenue
|
-14,977 | -12,839 | -10,435 | -8,308 | -7,129 |
|
Gross Profit
|
45,718 | 39,386 | 30,581 | 23,477 | 20,048 |
| Selling, General and Administrative Expenses
|
-27,126 | -24,501 | -21,031 | -21,638 | -24,317 |
|
Research and Development Expenses
|
-11,027 | -9,603 | -7,190 | -6,665 | -7,678 |
| Depreciation, Amortization and Depletion
|
-395 | -395 | -399 | -278 | -455 |
| Provision Expense/Write-Back
|
-564 | -564 | -570 | 145 | -281 |
|
Operating Income/Expenses
|
-38,153 | -35,063 | -29,190 | -28,436 | -32,731 |
|
Total Operating Profit/Loss
|
7,565 | 4,323 | 1,391 | -4,959 | -12,683 |
| Total Net Finance Income/Expense
|
2,112 | 1,371 | 1,121 | 1,297 | -107 |
| Net Investment Income
|
2,016 | 2,016 | 947 | -284 | -244 |
|
Non-Operating Income/Expenses, Total
|
2,112 | 3,387 | 2,068 | 1,013 | -351 |
|
Pretax Income
|
9,677 | 7,710 | 3,459 | -3,946 | -13,034 |
|
Provision for Income Tax
|
-178 | -135 | -538 | -251 | -315 |
|
Net Income from Continuing Operations
|
9,499 | 7,575 | 2,921 | -4,197 | -13,349 |
|
Net Income after Extraordinary Items and Discontinued Operations
|
9,499 | 7,575 | 2,921 | -4,197 | -13,349 |
|
Net Income after Non-Controlling/Minority Interests
|
9,499 | 7,575 | 2,921 | -4,197 | -13,349 |
|
Net Income Available to Common Stockholders
|
9,499 | 7,575 | 2,921 | -4,197 | -13,349 |
|
Dilution to Earnings
|
-358 | -358 | -996 | 0 | -- |
|
Diluted Net Income Available to Common Stockholders
|
9,499 | 7,217 | 1,925 | -4,197 | -13,349 |
| Basic EPS
|
0.25 | 0.20 | 0.09 | -0.13 | -0.40 |
| Diluted EPS
|
0.23 | 0.18 | 0.05 | -0.13 | -0.40 |
|
Basic Weighted Average Shares Outstanding
|
39,248.79 | 39,605.52 | 34,768.96 | 33,155.67 | 32,981 |
|
Diluted Weighted Average Shares Outstanding
|
39,248.79 | 39,605.52 | 34,768.96 | 33,155.67 | 32,981 |
| Income Statement, Supplemental
|
|||||
|
EBIT
|
7,565 | 5,270 | 1,109 | -6,069 | -14,097 |
|
EBITDA
|
9,228 | 6,808 | 2,880 | -4,732 | -12,563 |
|
Normalized EBITDA
|
10,623 | 7,058 | 4,440 | -2,389 | -9,675 |
|
Normalized Income
|
10,802.57 | 8,278.46 | 4,579.53 | -2,617.73 | -11,591.86 |
|
Total Unusual Items
|
1,328 | 716 | 1,964 | 2,051 | 2,282 |
12/31/2022 - 3/28/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade